Catalyst Brief

← Calendar

Readoutin 13d

Eisai Inc. — Lecanemab IV

Phase 3 primary completion: A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease.

Date
Dec 2026
Type
Readout
Indication
Early Alzheimer's Disease

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.